[Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis].
Gallardo
R
R
Fobelo
M J
MJ
Pastor
C
C
Orta-Cuevas
J C
JC
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D002744:Chlorpheniramine / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D004334:Drug Administration Schedule; D005483:Flushing / Q000139:chemically induced / Q000517:prevention & control; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011292:Premedication; D025241:Spondylarthritis / Q000188:drug therapy*; D013546:Sweating / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D006634:Histamine H1 Antagonists; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; C018904:dexchlorpheniramine; D002744:Chlorpheniramine; D000069285:Infliximab; D008775:Methylprednisolone
Protocolo de inducción de tolerancia a infliximab en paciente con espondilartropatía psoriásica.